AstraZeneca to Shut R&D Sites

March 2, 2010
Sites will be closed in Britain, Sweden and activities reduced in Delaware facility

Pharmaceutical giant AstraZeneca on March 2 said it would shut research and development sites in Britain and Sweden and reduce U.S. operations as part of previously announced plans to axe 8,000 jobs.

The company had said in January said that it was looking to cut 8,000 jobs worldwide by 2014, including 3,500 R&D positions.

On March 2 it said it would close an R&D center in Leicestershire, central England, and a smaller site in Cambridge, close to London.

It added that it would shut a research site in Lund, Sweden, and reduce activities at a facility in Wilmington, Delaware.

"AstraZeneca today shared with its employees further details of proposals designed to improve the productivity of its global research and development organization," the group said.

"The proposed changes, first outlined at the end of January, include focusing research efforts on a smaller number of disease areas and consolidating activities onto a reduced global footprint through the merger of some sites. Some of our sites will close," it added.

Copyright Agence France-Presse, 2010

Popular Sponsored Recommendations

Process Mining For Dummies

Nov. 19, 2023
Here it is. Everything you need to know about process mining in a single book, written in the easy-to-understand, hard-to-forget style that ‘For Dummies’ manages so effortlessly...

How Digital Twin Technology is Empowering Manufacturers

Sept. 27, 2023
This FAQ delves into why this technology offers business value and considerations toward implementation.

Legacy Phone Lines Are Draining Your Profits

Oct. 30, 2023
Copper wire phone line expenses that support emergency devices could be costing your company millions of dollars in wasteful overhead expenses. Rates have been skyrocketing while...

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!